Avidity Partners 13F holdings, Q4 2023
Holdings as of December 31, 2023 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 72 US equity positions worth $2.6bn in its Q4 2023 13F filing. The largest position was ARVN at 4.7% of the reported book, followed by BSX and TMO. Against the Q3 2023 filing, it opened 7 new positions, added to 19 and reduced 23 among the top 50 holdings.
What did Avidity Partners own in Q4 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2023 |
|---|---|---|---|---|---|---|---|
| 1 | ARVN ARVINAS INC | Healthcare | 4.7% | $122.9m | 2,985,117 | 14% | added |
| 2 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 4.2% | $109.3m | 1,890,000 | -9% | reduced |
| 3 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 3.7% | $96.9m | 182,600 | – | new |
| 4 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 3.4% | $89.9m | 1,156,692 | 62% | added |
| 5 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.3% | $86.7m | 658,000 | 1% | added |
| 6 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.3% | $85.4m | 3,950,000 | 40% | added |
| 7 | NTRA NATERA INC | Healthcare | 2.7% | $69.5m | 1,110,000 | 23% | added |
| 8 | DHR DANAHER CORPORATION | Healthcare | 2.6% | $67.1m | 290,000 | 64% | added |
| 9 | THC TENET HEALTHCARE CORP | Healthcare | 2.5% | $65.8m | 871,000 | -10% | reduced |
| 10 | KARUNA THERAPEUTICS INC | 2.5% | $65.2m | 206,000 | -28% | reduced | |
| 11 | FUSION PHARMACEUTICALS INC | 2.4% | $62.5m | 6,500,328 | 12% | added | |
| 12 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.3% | $60.2m | 489,119 | -39% | reduced |
| 13 | REGN REGENERON PHARMACEUTICALS | Healthcare | 2.3% | $59.7m | 68,000 | 17% | added |
| 14 | CVS CVS HEALTH CORP | Healthcare | 2.2% | $58.4m | 740,000 | – | new |
| 15 | 2655787D BLUEPRINT MEDICINES CORP | 2.2% | $56.7m | 615,000 | -18% | reduced | |
| 16 | IMMUNOGEN INC | 2.1% | $54.2m | 1,829,215 | -5% | reduced | |
| 17 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 2.1% | $54.1m | 1,520,000 | -29% | reduced |
| 18 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 2.0% | $52.2m | 237,202 | – | new |
| 19 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 2.0% | $51.5m | 1,719,103 | 8% | added |
| 20 | INTRA-CELLULAR THERAPIES INC | 1.9% | $50.9m | 710,000 | -11% | reduced | |
| 21 | LLY ELI LILLY & CO | Healthcare | 1.9% | $49.5m | 85,000 | 13% | added |
| 22 | BHVN BIOHAVEN LTD | Healthcare | 1.9% | $49.1m | 1,148,308 | -11% | reduced |
| 23 | AVTR AVANTOR INC | Healthcare | 1.9% | $48.4m | 2,121,844 | – | new |
| 24 | ZTS ZOETIS INC | Healthcare | 1.8% | $47.4m | 240,000 | -8% | reduced |
| 25 | HUM HUMANA INC | Healthcare | 1.8% | $45.8m | 100,000 | -9% | reduced |
| 26 | ABBV ABBVIE INC | Healthcare | 1.7% | $44.1m | 284,405 | – | new |
| 27 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.7% | $44.0m | 1,080,000 | 116% | added |
| 28 | ALGN ALIGN TECHNOLOGY INC | Healthcare | 1.6% | $42.7m | 155,800 | – | new |
| 29 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.6% | $41.2m | 685,000 | -29% | reduced |
| 30 | BDX BECTON DICKINSON & CO | Healthcare | 1.5% | $40.4m | 165,706 | -42% | reduced |
| 31 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.5% | $40.4m | 844,500 | 55% | added |
| 32 | MCK MCKESSON CORP | Healthcare | 1.5% | $39.6m | 85,500 | -49% | reduced |
| 33 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.4% | $37.6m | 815,993 | 154% | added |
| 34 | SGRY SURGERY PARTNERS INC | Healthcare | 1.4% | $37.3m | 1,165,932 | -13% | reduced |
| 35 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.4% | $36.6m | 459,400 | 55% | added |
| 36 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 1.4% | $36.4m | 6,360,212 | 5% | added |
| 37 | PCVX VAXCYTE INC | Healthcare | 1.4% | $35.8m | 570,137 | -25% | reduced |
| 38 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 1.3% | $33.9m | 1,990,632 | 11% | added |
| 39 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.3% | $33.7m | 1,142,850 | 0% | held |
| 40 | UNH UNITEDHEALTH GROUP INC | Healthcare | 1.2% | $30.8m | 58,500 | -48% | reduced |
| 41 | PRVA PRIVIA HEALTH GROUP INC | Healthcare | 1.1% | $29.6m | 1,287,000 | -17% | reduced |
| 42 | ISRG INTUITIVE SURGICAL INC | Healthcare | 1.1% | $28.7m | 85,000 | – | new |
| 43 | LNTH LANTHEUS HLDGS INC | Healthcare | 0.9% | $23.6m | 380,000 | -32% | reduced |
| 44 | ANTX AN2 THERAPEUTICS INC | 0.9% | $23.4m | 1,140,000 | 5% | added | |
| 45 | ACIU AC IMMUNE SA | Healthcare | 0.9% | $22.3m | 4,469,080 | 50% | added |
| 46 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 0.8% | $21.8m | 714,000 | -33% | reduced |
| 47 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.8% | $20.5m | 300,200 | -14% | reduced |
| 48 | CRINETICS PHARMACEUTICALS IN | 0.7% | $18.8m | 529,000 | -13% | reduced | |
| 49 | PHAT PHATHOM PHARMACEUTICALS INC | 0.6% | $15.7m | 1,721,580 | 6% | added | |
| 50 | VRNA VERONA PHARMA PLC | 0.6% | $15.5m | 780,900 | -6% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.